Jiangsu Recbio Technology Co., Ltd. Increases Production For The First Phase Of Manufacturing Facility With A Maximum Annual Output Of 20 Million Doses Of Recombinant HPV 9-Valent Vaccine

/PRNewswire/ -- (the "Company", together with its subsidiaries, the "Group") on voluntary basis. The board of directors of the Company (the "Board") is pleased...

Related Keywords

China ,Taizhou ,Jiangsu ,Hong Kong , ,Stock Exchange Of Hong Kong ,Jiangsu Recbio Technology Co Ltd ,World Health Organization ,Company The Board ,Good Manufacturing Practices ,Press Release ,Stock Exchange ,Hong Kong Limited ,Jiangsu Recbio Technology Co ,Td ,